Zolgensma is a prescription drug that’s used to treat spinal muscular atrophy (SMA) in young children. Zolgensma’s cost may depend on factors such as your child’s treatment plan and whether ...

Zolgensma works by replacing the missing or nonfunctioning gene causing S.M.A. with a working copy of the gene. It has been given to more than 2,500 children and approved for use in 46 countries.

The only other treatment for SMA is a drug called Spinraza (made by Biogen). But unlike Zolgensma, which is administered just once, Spinraza must be taken for life. The first year of Spinraza costs ...

Zolgensma: A Remarkable New Treatment, An ICER Analysis, And A Poorly Justified Price Peter B. Bach June 18, 2019 10.1377/forefront.20190617.50453 Sections ...

The High Cost of Precision To understand why a single dose of a drug costs $2.1 million, you have to start by looking at how it is manufactured and why it was created in the first place. Zolgensma ...

Since an initial FDA nod in 2019, Zolgensma has been cleared in over 40 countries and has become a blockbuster therapy. It reeled in $379 million in sales in the second quarter, a 26% increase ...

The drugmaker knew about Zolgensma's inaccurate data on March 14 but did not tell the FDA until June 28, more than one month after the agency approved the drug, the agency said.

Zolgensma is an adeno-associated virus vector-based gene therapy. The Food and Drug Administration (FDA) has approved several revisions to the prescribing information for Zolgensma (onasemnogene ...